Serum India Limited

The first batches of Covishield, the Serum Institute of India's coronavirus vaccine, left Pune early this morning for Delhi and 12 other cities, four days ahead of the nationwide inoculation drive against COVID-19.

As the race for a COVID-19 vaccine intensifies, Bangladesh's leading pharma company Beximco has announced it will be investing in Adar Poonawalla's Serum India Limited (SIL) for development of the vaccine. The size of the investment has not been disclosed but will depend on SIL's priority supply commitment to Beximco Pharma Ltd (BPL).

The first batches of Covishield, the Serum Institute of India's coronavirus vaccine, left Pune early this morning for Delhi and 12 other cities, four days ahead of the nationwide inoculation drive against COVID-19.

As the race for a COVID-19 vaccine intensifies, Bangladesh's leading pharma company Beximco has announced it will be investing in Adar Poonawalla's Serum India Limited (SIL) for development of the vaccine. The size of the investment has not been disclosed but will depend on SIL's priority supply commitment to Beximco Pharma Ltd (BPL).